| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:51 UTC |
|---|
| Update Date | 2023-02-21 17:18:22 UTC |
|---|
| HMDB ID | HMDB0015052 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Metronidazole |
|---|
| Description | Metronidazole, also known as metrogel-vaginal or flagyl, belongs to the class of organic compounds known as nitroimidazoles. Nitroimidazoles are compounds containing an imidazole ring which bears a nitro group. Metronidazole is a moderately basic compound (based on its pKa). Metronidazole is formally rated as a possible carcinogen (by IARC 2B) and is also a potentially toxic compound. |
|---|
| Structure | CC1=NC=C(N1CCO)[N+]([O-])=O InChI=1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3 |
|---|
| Synonyms | | Value | Source |
|---|
| 1-(2-Hydroxy-1-ethyl)-2-methyl-5-nitroimidazole | ChEBI | | 1-(2-Hydroxyethyl)-2-methyl-5-nitroimidazole | ChEBI | | 1-(beta-Ethylol)-2-methyl-5-nitro-3-azapyrrole | ChEBI | | 1-(beta-Hydroxyethyl)-2-methyl-5-nitroimidazole | ChEBI | | 1-(beta-Oxyethyl)-2-methyl-5-nitroimidazole | ChEBI | | 2-Methyl-1-(2-hydroxyethyl)-5-nitroimidazole | ChEBI | | 2-Methyl-3-(2-hydroxyethyl)-4-nitroimidazole | ChEBI | | 2-Methyl-5-nitroimidazole-1-ethanol | ChEBI | | Metronidazol | ChEBI | | Metronidazolum | ChEBI | | Flagyl | Kegg | | Metrogel-vaginal | Kegg | | Noritate | Kegg | | 1-(b-Ethylol)-2-methyl-5-nitro-3-azapyrrole | Generator | | 1-(Β-ethylol)-2-methyl-5-nitro-3-azapyrrole | Generator | | 1-(b-Hydroxyethyl)-2-methyl-5-nitroimidazole | Generator | | 1-(Β-hydroxyethyl)-2-methyl-5-nitroimidazole | Generator | | 1-(b-Oxyethyl)-2-methyl-5-nitroimidazole | Generator | | 1-(Β-oxyethyl)-2-methyl-5-nitroimidazole | Generator | | Noritic acid | Generator | | Methronidazole | HMDB | | Metronidazole benzoate | HMDB | | Metronidazole in plastic container | HMDB | | Metronidazolo | HMDB | | Danizol | HMDB | | Gineflavir | HMDB | | Metric | HMDB | | Metrodzhil | HMDB | | Metrogyl | HMDB | | Metronidazole phosphoester | HMDB | | Metronidazole hydrochloride | HMDB | | Phosphoester, metronidazole | HMDB | | 2 Methyl 5 nitroimidazole 1 ethanol | HMDB | | Clont | HMDB | | Metronidazole phosphate | HMDB | | Phosphate, metronidazole | HMDB | | Trivazol | HMDB | | Bayer 5360 | HMDB | | Hydrochloride, metronidazole | HMDB | | MetroGel | HMDB | | Metronidazole monohydrochloride | HMDB | | Monohydrochloride, metronidazole | HMDB | | Satric | HMDB | | Trichazol | HMDB | | Trichopol | HMDB | | Vagilen | HMDB |
|
|---|
| Chemical Formula | C6H9N3O3 |
|---|
| Average Molecular Weight | 171.154 |
|---|
| Monoisotopic Molecular Weight | 171.064391169 |
|---|
| IUPAC Name | 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethan-1-ol |
|---|
| Traditional Name | metronidazole |
|---|
| CAS Registry Number | 443-48-1 |
|---|
| SMILES | CC1=NC=C(N1CCO)[N+]([O-])=O |
|---|
| InChI Identifier | InChI=1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3 |
|---|
| InChI Key | VAOCPAMSLUNLGC-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as nitroimidazoles. Nitroimidazoles are compounds containing an imidazole ring which bears a nitro group. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Azoles |
|---|
| Sub Class | Imidazoles |
|---|
| Direct Parent | Nitroimidazoles |
|---|
| Alternative Parents | |
|---|
| Substituents | - 1,2,5-trisubstituted-imidazole
- Nitroaromatic compound
- Nitroimidazole
- Trisubstituted imidazole
- N-substituted imidazole
- Heteroaromatic compound
- Organic nitro compound
- C-nitro compound
- Alkanolamine
- Azacycle
- Organic 1,3-dipolar compound
- Propargyl-type 1,3-dipolar organic compound
- Allyl-type 1,3-dipolar organic compound
- Organic oxoazanium
- Hydrocarbon derivative
- Primary alcohol
- Organooxygen compound
- Organonitrogen compound
- Organic oxide
- Organopnictogen compound
- Organic zwitterion
- Organic oxygen compound
- Organic nitrogen compound
- Alcohol
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 160 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 5.92 g/L | Not Available | | LogP | -0.1 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 1.82 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 9.6356 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.16 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 51.6 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1044.4 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 300.5 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 78.0 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 170.8 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 48.6 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 251.0 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 287.9 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 297.9 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 640.7 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 136.3 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1056.0 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 199.3 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 180.6 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 483.1 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 222.7 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 273.3 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized |
|---|
| General References | - Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP: Lack of disulfiram-like reaction with metronidazole and ethanol. Ann Pharmacother. 2002 Jun;36(6):971-4. [PubMed:12022894 ]
- Williams CS, Woodcock KR: Do ethanol and metronidazole interact to produce a disulfiram-like reaction? Ann Pharmacother. 2000 Feb;34(2):255-7. [PubMed:10676835 ]
- Lamont RF: Can antibiotics prevent preterm birth--the pro and con debate. BJOG. 2005 Mar;112 Suppl 1:67-73. [PubMed:15715599 ]
- Shennan A, Crawshaw S, Briley A, Hawken J, Seed P, Jones G, Poston L: A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study. BJOG. 2006 Jan;113(1):65-74. [PubMed:16398774 ]
|
|---|